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Assays of mitochondrial electron transport system (ETS) activity in circulating blood platelets have
been used to investigate the cause of neurodegenerative diseases. However, the correspondence
between platelet ETS function and cerebral mitochondrial metabolism is not well characterized. To
assess the validity of using platelet ETS activity to infer cerebral mitochondrial metabolism, we
measured platelet ETS activity (complex I and complex I + III), cerebral metabolic rate of oxygen
(CMRO2), and the CMRO2/cerebral metabolic rate for glucose ratio in 40 subjects: 7 with never-
medicated Parkinson’s disease, 13 with genetically proved Huntington’s disease, and 20 normal
controls. We found no correlation between in vivo measures of cerebral mitochondrial oxidative
metabolism and ex vivo assays of platelet complex I and complex I + III activity performed on blood
collected immediately before cerebral metabolism studies. We saw no evidence of a threshold effect
when comparing platelet complex I and complex I + III activity with cerebral oxidative metabolism
across a 4- to 10-fold range of platelet ETS activity. On the basis of these data, we conclude that
measures of mitochondrial complex I and I + III activity in platelets within the ranges we have studied
do not correlate with oxidative function of cerebral mitochondria.
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Introduction
Assays of mitochondrial electron transport system
(ETS) activity in circulating blood platelets from
patients with Alzheimer’s disease, Huntington’s
disease (HD), and Parkinson’s disease (PD) have
been used to investigate the cause of neurodegenera-
tion in these conditions (Parker et al, 1990; Krige
et al, 1992; Haas et al, 1995; Blake et al, 1997;
Blandini et al, 1998; Cardoso et al, 2004). However,
the correspondence between platelet ETS assays and
cerebral mitochondrial metabolism is not well—
characterized. Specific defects in cerebral mitochon-
drial ETS decrease the cerebral metabolic rate of
oxygen (CMRO2) proportionately more than the
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cerebral metabolic rate for glucose (CMRglc) (fewer
moles of oxygen consumed per mole of glucose
metabolized), thereby producing a reduction in the
CMRO2/CMRglc ratio below the normal value of 5.6
(Frackowiak et al, 1988; Shishido et al, 1996). This is
in distinction to the situation during physiologic
brain activation in which the CMRO2/CMRglc ratio
is also below normal, but CMRO2 is not reduced
(Dienel et al, 2002). Therefore, in vivo assessment of
cerebral mitochondrial energy metabolism requires
combined measurement of both CMRO2 and CMRglc.
To assess the general validity of using platelet ETS
activity to infer abnormalities in cerebral mitochon-
drial metabolism in neurodegenerative diseases
as compared with normal controls, we compared
platelet ETS activity (complex I and complex I + III)
with CMRO2 and the CMRO2/CMRglc ratio in 40
subjects: 7 with never-medicated PD, 13 with
genetically proved HD, and 20 normal controls.
Materials and methods
Subjects
Subjects for this report were selected from a larger study of
mitochondrial ETS function in neurodegenerative diseases
because they had blood for platelet ETS assays drawn
immediately before positron emission tomography (PET)
measurements of CMRO2 and CMRglc (Powers et al,
2007a, b, 2008). Inclusion and exclusion criteria for PD,
HD, and normal controls have been published previously
(Powers et al, 2007a, b, 2008). None of the subjects were
taking medications that interfered with mitochondrial
function.
In Vitro Measurements of Platelet Electron Transport
System Complex Activity
In all, 100 ml of blood anticoagulated with sodium citrate
solution was collected immediately before PET and
shipped to UCSD (University of California, San Diego)
Mitochondrial Disease Laboratory for analysis. Samples
were labeled only with coded numbers. The identification
of individual subjects and their diagnoses remained at
Washington University and was not available to the
investigators at UCSD.
Complex I and citrate synthase activities were measured
using established techniques (Haas et al, 1995; Shults et al,
1997). Complex I + III activity was measured as rotenone-
sensitive NADH cytochrome c reductase activity. Citrate
synthase activity measurements were used to calculate
values normalized for any differences in mitochondrial
mass.
Image Acquisition
High-resolution T1-weighted magnetic resonance (MR)
images were acquired using a Siemens Magnetom SONA-
TA 1.5-T scanner (Siemens Medical Solutions USA Inc.,
Malvern, PA, USA). A mid-sagittal scout spin-echo
sequence was used to position the subject, and then a
three-dimensional MPRAGE sequence was acquired (repe-
tition time/echo time/inversion time (TI) = 1,900/3.93/
1,100 milliseconds, FA = 81, 7:07 minutes, 128 256 256
matrix 1.25 1 1 mm3 voxels).
Positron emission tomography images were obtained in
the two-dimension acquisition mode using a Siemens/CTI
ECAT EXACT HR 47 PET scanner (Siemens Medical
Solutions USA Inc., Knoxville, TN, USA) with participants
lying supine in a quiet dark room. Cerebral blood flow,
cerebral blood volume, CMRO2, and oxygen extraction
fraction were measured as described previously (Raichle
et al, 1983; Mintun et al, 1984; Martin et al, 1987; Powers
et al, 2007b). Dynamic emission PET scans were obtained
after slow intravenous injection over 10 to 20 seconds of
10 mCi of 18F-fluorodeoxyglucose (18FDG) for measurement
of CMRglc (Powers et al, 2007b). All PET emission scans
were reconstructed with filtered back projection using
individual attenuation measurements and scatter correc-
tion with a ramp filter cutoff at the Nyquist frequency,
producing images with a resolution of 4.3 mm full-width at
half maximum.
Image Analysis
The 1.5-T MR image was segmented into the brain and
cerebrospinal fluid based on voxel intensities. Manual
editing was required to remove the external tissue in which
there was insufficient cerebrospinal fluid to separate the
brain (near sinuses, temporal lobes, eyes, and brainstem),
and a single erosion followed by conditional dilation
completed the tissue segmentation. The MR image was
then edited manually to generate a region of interest
encompassing both cerebral hemispheres by removing the
cerebellum and brainstem along a plane connecting the
posterior commissure and the most inferior point of the
interpeduncular fossa. For each participant, the striatum
(bilateral caudate and putamen) region of interest was
outlined on the MR image (Powers et al, 2007b).
The original segmented MR image plus the three 15O PET
images were coregistered to a composite 40 to 60 minutes
18FDG PET image using Automated Image Registration
software (AIR, Roger Woods, University of California, Los
Angeles, CA, USA) (Woods et al, 1993). Mean counts
corrected for partial volume effects owing to nonbrain
structures including cerebrospinal fluid were generated for
the bihemispheric regions of interest for each of the three
15O PET images and for the dynamic 18FDG PET images
(Videen et al, 1999). Corrected mean counts were converted
to quantitative cerebral blood flow, oxygen extraction
fraction, or CMRO2 (Videen et al, 1987).
For measurement of bihemispheric and striatal CMRglc,
a modified Marquardt parameter estimation routine was
used to derive rate constants for each participant using
partial volume-corrected dynamic 18FDG PET counts and
arterial whole-blood time-radioactivity curves (Powers et
al, 2007b). For this study, we calculated from our entire
series of 23 normal control subjects, aged 26 to 70 years, a
value for the lumped constant of 0.64 that yielded a mean
bihemispheric value for CMRO2/CMRglc equal to the value
of 5.6 that has been directly measured from arterial and
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jugular venous samples in normal adults, aged 21 to 69
years (Gottstein et al, 1963).
Statistical Analysis
Pearson’s bivariate correlation coefficients were calculated
using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).
Informed Consent
This research received previous approval from the
Washington University Human Studies Committee
(Institutional Review Board). Written informed consent
was obtained from each participant.
Results
Studies were performed in 40 subjects, aged 26 to 76
years: 7 with never-medicated PD, 13 with geneti-
cally proved HD, and 20 normal controls. There were
25 men and 15 women.
The range of measured values for platelet ETS was
4- to 10-fold, and that for cerebral metabolism was
2- to 3-fold (Table 1). There were no statistically
significant correlations between platelet ETS
activity and measures of hemispheric (Table 2,
Figures 1 and 2) or striatal (data not shown, all
P > 0.22) cerebral mitochondrial oxidative metabolism
(CMRO2/CMRglc or CMRO2). Correlations for the
individual groups (PD, HD, and normal controls)
were also not statistically significant (data not
shown, all P > 0.09).
Discussion
We used a method that corrects for artifactual
reductions in PET measurements caused by partial
volume effects from increases in ventricular and
sulcal cerebrospinal fluid volume. It will thus
produce accurate bihemispheric PET measurements
in HD and PD. The CMRO2 method that we have
used has been validated for quantitative accuracy in
nonhuman primates across a wide range of CMRO2
(Mintun et al, 1984; Altman et al, 1991). Included in
these validation studies were measurements during
intraaortic sodium cyanide infusion, specifically
showing the accuracy of this technique to accurately
Table 1 Ranges of measured values
Complex I activity (nmol/mg per min) 6.8–33.4
Complex I activity/citrate synthase activity 0.0236–0.1108
Complex I+III activity (nmol/mg per min) 5.6–52.2
Complex I+III activity/citrate synthase activity 0.0114–0.1200
CMRO2 (mmol/100 g per min) 67.6–203.79
CMRglc (mmol/100 g per min) 13.8–28.0
CMRO2/CMRglc 3.4–9.1
CMRglc, cerebral metabolic rate for glucose; CMRO2, cerebral metabolic rate
of oxygen.
Table 2 Correlation coefficients for platelet ETS activity and
cerebral oxidative metabolism
CI CI/CS CI+III CI+III/CS
CMRO2/CMRglc
Pearson’s r 0.039 0.139 0.040 0.040
P-value (two tailed) 0.809 0.393 0.804 0.806
CMRO2
Pearson’s r 0.055 0.063 0.178 0.131
P-value (two tailed) 0.735 0.700 0.273 0.421
CMRO2, hemispheric cerebral metabolic rate for oxygen (mmol/100 g per
min); CMRglc, hemispheric cerebral metabolic rate for glucose (mmol/100 g
per min); CI, Complex I activity (nmol/mg per min); CI/CS, Complex I activity/
citrate synthase activity; CI+III, Complex I+III activity (nmol/mg per min); CI/
III/CS, Complex I+III activity/citrate synthase activity; ETS, electron transport
system.





















Figure 2 Relationship of platelet complex I + III activity to
hemispheric cerebral mitochondrial metabolism.





















Figure 1 Relationship of platelet complex I activity to hemi-
spheric cerebral mitochondrial metabolism.
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measure a reduction in CMRO2 under conditions of
reduced mitochondrial ETS activity. In measuring
CMRglc with 18FDG, we explicitly assumed that the
lumped constant value is the same for HD and PD as
it is for normal controls. In adults, the lumped
constant has been shown to change appreciably only
in tumors or under conditions when glucose delivery
becomes rate limiting for glucose metabolism, e.g.,
during ischemia and hypoglycemia (Crane et al,
1981; Nakai et al, 1987; Suda et al, 1990; Spence
et al, 1998). In our participants with HD and PD,
neither ischemia nor hypoglycemia was present.
Thus, our assumption that the lumped constant
value is the same for HD as it is for normal controls
is valid.
We found no correlation between in vivo PET
measures of cerebral mitochondrial oxidative meta-
bolism and ex vivo assays of platelet complex I and
complex I + III activity performed on blood collected
immediately before PET studies As with other
components of the ETS, complexes I and III both
show threshold effects, with changes in mitochon-
drial oxidative metabolism not occurring until com-
plex activity is reduced by 25% to 60% (Pathak and
Davey, 2008). We saw no evidence of such a thresh-
old effect when comparing platelet complex I and
complex I + III activity with cerebral oxidative meta-
bolism across a 4- to 10-fold range of platelet ETS
activity. On the basis of these data, we conclude that
measures of mitochondrial complex I and I + III
activity in platelets within the ranges we have
studied do not correlate with oxidative function of
cerebral mitochondria. Possible explanations for this
lack of correlation include: (1) platelet ETS activity is
not a good measure of brain ETS activity; (2)
variations in ETS activity are all above the thresholds
that result in reductions in oxygen metabolism; and
(3) as platelet ETS assays measure maximum possi-
ble substrate metabolism, the oxidation rate of the
resting brain is running substantially below the
maximum capacity of complexes I and I + III and
must be controlled by the activity of other ETS
complexes or by other factors.
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